ATAI Nasdaq IPO Stock Image

ATAI Nasdaq IPO Plans Announced

ATAI Life Sciences, a biopharmaceutical company headquartered in Berlin, announced that it is planning to raise $100 million to list on the Nasdaq Stock Exchange in an initial public offering.

The company, focused on developing psychedelic and non-psychedelic compounds for various mental health indications, submitted an S-1 filing to the Securities and Exchange Commission (SEC) on Tuesday. 

The filing shows that ATAI has raised an aggregate of $363.3 million in gross cash proceeds from the sale of its common stock and convertible notes to date. In November of last year, ATAI announced the closing of a $125 million funding round.

ATAI is planning to sell its shares on the Nasdaq exchange under the symbol ATAI. A date for the IPO has not been set.

Credit Suisse, Citigroup, Cowen, Berenberg, Cantor Fitzgerald, RBC, and Canaccord Genuity were listed as underwriters. 

Founded in 2018, ATAI operates as an umbrella for an impressive portfolio of wholly-owned and partner companies. Backed by top venture capitalists such as Peter Thiel, Steve Jurvetson, Thor Bjorgolfsson, and Mike Novogratz, ATAI’s R&D pipeline currently includes about 14 companies focusing on drug development and other technologies. In exchange for a stake in these companies, ATAI assists in conducting clinical trials, working with regulatory officials, and capital raises.

See Also
Natural Mushroom, Psilocybin and Amanita Muscaria

ATAI has also invested heavily in Compass Pathways, of which it owns an approximate 25 percent stake. Compass Pathways, a mental healthcare company focused on accelerating patient access to evidence-based innovation in mental health, was listed on the Nasdaq under the ticker “CMPS” in September and now has a valuation of around $1.2 billion. Its leading drug candidate, COMP360, has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA), for treatment-resistant depression (TRD). 

ATAI would join Compass Pathways as the second psychedelics-focused company to go public on the Nasdaq stock exchange.

What makes peyote unique among psychedelics?

Lophos Pharma is a #peyote focused psychedelics company co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s therapeutic potential.

Read the full interview here: http://ow.ly/kN6w50I3vzt

The push for medical #DMT is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from @mindmedco, @AlgernonPharma, @entheonbiomed, @SmallPharma and more.

Full article here: http://ow.ly/khee50HXOHz

#science #business #medicine

Our CEO and Co-Founder @flobrand spoke to @amanda_siebert @Forbes to give deeper context on the significance of our donation to @MAPS and the importance of collaboration between for-profit and non-profits in tackling the #mentalhealth crisis.

See: https://www.forbes.com/sites/amandasiebert/2022/02/16/exclusive-maps-accepts-500k-donation-from-atai-life-sciences-philanthropy-arm/

A Hawaii legislative committee has approved a bill that proposes the establishment of a working group to study the therapeutic benefits of #psilocybin by a vote of 5-0.

Read the full story here: http://ow.ly/4WWI50HWJtL

#psychedelics #healing #medicine #hawaii #legal

"Inspired by a device created by in the 1950s, the creators hope to bring free transcendental experiences to 100,000 Britons – and unite the country through communal hallucinations"

https://www.theguardian.com/artanddesign/2022/feb/16/dreamachine-unboxed-brion-gysin-jon-hopkins-assemble

Load More...

Related Articles

Scroll To Top